MBS Digest

A newsletter for anyone interested in the latest news about the obesity treatment space: research, technology, industry watch

[MBS Digest @MBSDigest]

https://t.co/K89h6J7iPV

[MBS Digest @MBSDigest]

New on The Staple Line, the weekly audio edition of MBS Digest.

Vol. 2, No. 18: cirrhosis that regressed after bariatric surgery, surgery after GLP-1 drugs fall short, heart and kidney outcomes, and retatrutide for knee pain, each with its catch.

Link in reply.

[MBS Digest @MBSDigest]

https://t.co/qZxiSzURli

[MBS Digest @MBSDigest]

MBS Digest N.º 18 (en español), Artículo de la Semana: con biopsias pareadas a 6,2 años, la cirrosis MASH compensada regresó en el 33% de 30 pacientes tras la cirugía bariátrica; cohorte pequeña y sin comparador, es una asociación. Enlace en la respuesta.

[MBS Digest @MBSDigest]

https://t.co/HybEHHEqm4

[MBS Digest @MBSDigest]

Across 16 randomized trials, exercise lowered liver fat (SMD -0.47) and the result held after robust correction; the ALT signal did not. The cartoon is a dramatization. MBS Digest Issue 18. Link in reply.

[MBS Digest @MBSDigest]

https://t.co/4UvamggK9J

[MBS Digest @MBSDigest]

New from the ASMBS: COMPASS, a free patient tool comparing lifestyle programs, anti-obesity medications, endoscopic procedures and metabolic surgery.

It shows weight lost in studies for the user's own weight, and risks as "X in 100 people."

Link in the reply.

[MBS Digest @MBSDigest]

ASMBS Weekend in Las Vegas is a chance to learn, connect and improve care. The Medicare payment cuts are a sobering backdrop. How can the specialty turn meeting momentum into a stronger voice for patient access?
https://t.co/UOc32o1A0l
https://t.co/ScPHn6jilC

[MBS Digest @MBSDigest]

A troubling payment outlook meets a reason for optimism: CMS lists a 2.31% drop in the 2027 non-APM conversion factor, while ASMBS Weekend brings bariatric teams together in Las Vegas, Nov. 5-7.
https://t.co/UOc32o1A0l
https://t.co/ScPHn6jilC

[MBS Digest @MBSDigest]

https://t.co/bKBWk7iMhe

[MBS Digest @MBSDigest]

New in MBS Digest: an editorial by Editor-in-Chief Shanu N. Kothari, MD, FACS, on why metabolic bariatric surgery is still seen as high-risk. He cites MBSAQIP 30-day mortality of 0.06% to 0.1% and argues the gap is in how results are communicated. Link in reply.

[MBS Digest @MBSDigest]

Also on Apple Podcasts, Spotify and Amazon Music:
https://t.co/QcxtHQztZq
https://t.co/ehSUE8615e
https://t.co/1G0xwgeGDU

[MBS Digest @MBSDigest]

New on The Staple Line, the audio edition of MBS Digest Vol. 2, Issue 17: the Article of the Week on how far bariatric volume has fallen, bypass versus sleeve at five years, gastroparesis, and a robotic learning curve.

Listen: https://t.co/UpQjByocOk

[MBS Digest @MBSDigest]

https://t.co/w5e0aFH3bL

[MBS Digest @MBSDigest]

In 1,456,480 MBSAQIP operations, 30-day readmissions for dehydration or kidney injury fell from 1.2% to 0.5% after sleeve and 1.8% to 0.9% after bypass (2015-2023). Registry codes can't show what drove it; the cartoon is a dramatization. MBS Digest Issue 17. Link in reply.

[MBS Digest @MBSDigest]

https://t.co/jLjVAX6PIg

[MBS Digest @MBSDigest]

The MBS Digest: the week in metabolic and bariatric science, chosen by a board of surgeons and clinicians, in English and Spanish. Now also The Staple Line, the podcast.

[MBS Digest @MBSDigest]

https://t.co/b8ZQTkkmxy

[MBS Digest @MBSDigest]

La Dra. Donna Ryan se suma al Consejo Editorial de MBS Digest como Editora de Medicina de la Obesidad. Profesora emérita de Pennington Biomedical, expresidenta de la Federación Mundial de Obesidad y de The Obesity Society, y copresidenta del comité directivo de SELECT.